Denosumab biosimilar for treating postmenopausal osteoporosis

Denosumab biosimilar is in clinical development for the treatment of postmenopausal women with osteoporosis. Osteoporosis is a condition that causes weakening of the bones, which can result in increased risk of fractures or breaks. Women are at increased risk of osteoporosis because the female hormone, oestrogen, drops significantly after menopause, resulting in a rapid decrease of bone density. The patients affected by osteoporosis perceive it as a disease affecting their personal life with undesirable consequences such as chronic pain, impaired physical ability, reduced social activity, poor well-being, and depressed mood. The treatment of osteoporosis and prevention of fractures are vital for improving patients’ health and reducing hospital burden.